LETTERS TO THE EDITOR
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity
Article first published online: 4 SEP 2012
© 2012 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 10, Issue 9, pages 1946–1949, September 2012
How to Cite
LHERMUSIER, T., VOISIN, S., MEJEAN, S., GARCIA, C., SIÉ, P. and CARRIÉ, D. (2012), Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. Journal of Thrombosis and Haemostasis, 10: 1946–1949. doi: 10.1111/j.1538-7836.2012.04838.x
- Issue published online: 4 SEP 2012
- Article first published online: 4 SEP 2012
- Accepted manuscript online: 2 JUL 2012 07:22PM EST
- Received 5 April 2012, accepted 22 June 2012
- 1ESC Committee for Practice Guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 2011; 23: 2999–3054., , , , , , , , , , , , , , , , ,
- 2Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), , , , , , , , , , , , , , , , , , et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 20: 2501–55.
- 4TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31., , , , , , ,
- 10A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity for outcome validation effort) study. J Am Coll Cardiol Cardiovasc Interv 2012; 5: 281–9., , , , , , , , , , .